



Plot No. 2-B, Sector - 126, NOIDA-201304, Distt. Gautam Budh Nagar (Uttar Pradesh), Tel.: +91 (120) 6860000, 3090100, 3090200 Fax: +91 (120) 3090111, 3090211, E-mail: iglho@indiaglycols.com, Website: www.indiaglycols.com

The Manager (Listing)

Bandra Kurla Complex,

Bandra (East),

Mumbai- 400 051

Exchange Plaza, C-1, Block G,

National Stock Exchange of India Limited

6th November, 2023

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 500201 Symbol: INDIAGLYCO

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Investor Presentation

Further to our letter dated 27th October, 2023 and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, an investor presentation is attached for the information of the investors.

This same is also being hosted on the Company's website at www.indiaglycols.com.

This is for your information and record.

Thanking you,


Yours truly,

For India Glycols Limited

Ankur Jain Head (Legal) & Company Secretary Encl: A/a

CIN: L24111UR1983PLC009097





India Glycols Limited

Investor Presentation Q2 & H1 FY 2023-24

Safe Harbour Statement



This presentation and the following discussion may contain "forward looking statements" by India Glycols Limited ("IGL" or the company) that are not historical in nature. These forward-looking statements, which may include statements relating to future results of operations, financial condition, business prospects, plans and objectives, are based on the current beliefs, assumptions, expectations, estimates, and projections of the management of IGL about the business, industry and markets in which IGL operates.


These statements are not guarantees of future performance, and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond IGL's control and difficult to predict, that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Such statements are not, and should not be construed, as a representation as to future performance or achievements of IGL.

In particular, such statements should not be regarded as a projection of future performance of IGL. It should be noted that the actual performance or achievements of IGL may vary significantly from such statements.






Q2FY24 vs Q2FY23







Net Turnover 775 Cr +15.7%

EBITDA Margin
13.5%
+257 bps

PAT Margin
4.8%
+135 bps


- Witnessed overall a strong quarter with the healthy improvement in revenue and profitability
- Margins also delivered a robust expansion
- In-house Grain based ethanol, resulting in better margins from BSPC and PS segments


Consolidated Financials



H1FY24 vs H1FY23







Net Turnover
1,464 Cr
-1.0%

EBITDA Margin
14.3%
+474 bps

PAT Margin
6.0%
+ 259 bps

- Registered marginal increase in gross revenue
- Discontinued some low margin BSPC business as compared to H1FY23, impacted net turnover and has a positive affect on the overall margins
- High international ethanol prices have been mitigated with own Grain based ethanol, resulting in better operating margins


Consolidated Financials




Figures in Rs. Cr.










Ennature Biopharma (EB)



Highlights – Q2 & H1 FY24



Business Performance

Q2 FY24 over Q2 FY23

- Gross Revenue at Rs. 1,870 Cr, up 14.5% YoY; Net revenue saw a growth of 15.7% at Rs. 775 Cr
 - o BSPC Net Revenue reported a healthy growth of 14.8% YoY
 - o PS Net Revenue saw a robust increase of 26.1% YoY
- ☐ EBITDA stood at Rs. 106 Cr in Q2 registered excellent EBITDA growth of 43.4% YoY
 - o EBITDA margin at 13.5%, up 257 bps
- In-house Grain based capacity has been a major factor helped the company in mitigating the impact of cost increases in PS and BSPC
 - BSPC EBIT margin was by 177 bps to 8.2%
 - o PS EBIT improved by 487 bps to 18.0% in Q2
- □ PAT up by 61.2% YoY and stood at Rs. 38 Cr in Q2
 - o PAT Margin at 4.8%, up by 135 bps

H1 FY24 over H1 FY23

- □ For H1, Gross revenue up +7.5%; net revenue declined marginally by 1% in H1 over H1 FY23
 - Net revenue was mainly supported by uptick in revenue of PS segment by 19.9% YoY
- □ EBITDA up +48.5% YoY and stood at Rs. 212 Cr with EBITDA margin at 14.3% up by 474 bps
- Sharp improvement in EBITDA margin on account of discontinuation of low margin BSPC business and positive impact of installation of Grain based capacities has helped the margins
 - □ BSPC EBIT up by 385 YoY
 - □ PS EBIT up by 637 YoY

Highlights – Q2 & H1 FY24



Other Highlights


- ☐ Grain based ethanol capacities have helped mitigate impact of ethanol cost increases
- □ Cost pressures continue with high international ethanol prices has been a significant headwind. However, some signs of softening in future.
- □ EB, commenced production of Nicotine at Kashipur doubling the capacity. Continued focus on building the branded nutraceuticals range
- □ Current capacity in grain-based ethanol will be used for PS and Biofuels helping both topline and bottom-line growth
- □ NSU project execution in progress Phase 1 commissioned by May 23, Phase 2 expected to be commissioned by end 2023. Healthy Product and Business Development Pipeline work in progress
 - o NSU project execution full commissioning by year end. Commercial supplies have started
- Shakumbari Sugar and Allied Industries Limited (SSAIL) (Subsidiary of IGL) received the last and final tranche for Rs. 11.76 Cr on 08.Sep.2023 for the sale of IGL's entire stake in SSAIL in addition to advance amount of Rs 78.70 Cr received on 07.Aug.2023

Business Segment Highlights



















Bio-based Specialties and Performance Chemicals (BSPC)

- □ Q2 Revenue at Rs. 508 Cr., up 14.8%
- □ EBIT Q2 at Rs. 42 Cr., up 46.4%, EBIT margin at 8.2% up 177 bps
- □ H1 Revenue down by 8.3%
- □ EBIT H1 at Rs. 83 Cr., up 58.6%, EBIT margin at up 385 bps stood at 9.1%
- ☐ Grain ENA is now available post commissioning of production. Working on optimizing the costs
- □ Selective in doing profitable business. Bio-fuels represents an opportunity
- □ Reduction in sea freight helped to increase the export realization
- Focus on selling Grain based ENA over molassesbased ENA. Nearly all Molasses customers shifted to Grain
- □ Focus area : rationalizing procurement costs, hedging and inventory management, making right choice of customers for best possible realizations

Potable Spirits (PS)

- □ Q2 Revenue at Rs. 221 Cr., up by 26.1%
- □ EBIT for Q2 at Rs. 40 Cr., up 72.6%, EBIT margin at 18.0% up 487 bps
- □ H1 Revenue up by 19.9%
- □ EBIT H1 at Rs. 83 Cr., up 84.7%, EBIT margin at up 637 bps stood at 18.2%
- □ Growth driven by CL in UP & UK. New business in para-military, IMFL growth in Delhi and UK
- □ Uptake in premium brands across operating states
- □ In-house manufacturing of grain-based ENA enable margin improvement
- □ Usage of recycled packaging material also enabling the improvement of margins
- □ Raw material & packaging costs are stabilizing, thereby enabling margin improvement

Ennature Biopharma (EB)

- □ Q2 Revenue at Rs. 46 Cr., down 11.6%
- □ EBIT for Q2 at Rs. 7 Cr; EBIT margin at 14.9%
- ☐ H1 Revenue at Rs. 99 Cr; EBIT margin at 19.9%
- □ Nicotine sales faced strong headwinds due to persistent pressure on prices
- ☐ Focus remains on efficiency initiatives and aggressive diversification of customer base in the short run
- Continued to maintain leadership position in Thiocolchicoside with growth in export market share
- Upward trajectory in prices will translate to better margins for Thiocolchicoside and Colchicine from Q3 onwards
- Focus on strong science to build a robust Nutraceuticals portfolio

Consolidated Financials

Financial Summary - Consolidated



								INDIA GLYCOLS I
Particulars (In INR Cr)	Q2FY24	Q2FY23	Y-o-Y (%)	Q1FY24	Q-o-Q (%)	H1FY24	H1FY23	Y-o-Y (%)
Revenue from operations (net of excise)	775	670	15.7%	689	12.4%	1,464	1,478	(1.0%)
Other Income	11	6		6		17	12	
Total Income	785	676	16.2%	695	13.0%	1,480	1,490	(0.7%)
Cost of Material Consumed	497	425		398		896	956	
% of Sales	63.3%	62.9%		57.3%		60.5%	64.1%	
Employee Benefit Expenses	23	20		23		46	40	
% of Sales	3.0%	3.0%		3.3%		3.1%	2.7%	
Other Expenses	159	156		168		327	352	
% of Sales	20.2%	23.1%		24.2%		22.1%	23.6%	
EBITDA	106	74	43.4%	106	0.4%	212	143	48.5%
EBITDA Margin	13.5%	11.0%	257 bps	15.2%	(170 bps)	14.3%	9.6%	474 bps
Depreciation	28	21		21		48	43	
EBIT	78	53	48.7%	85	(8.2%)	164	100	63.6%
Finance Cost	29	24		28		57	46	
Exceptional Items	-	-		-		-	-	
Share of net profit / (loss) of joint venture	1	3		6		7	12	
РВТ	50	31	59.5%	64	(21.4%)	114	66	72.2%
Tax Expenses	12	8		13		25	15	
Profit / (Loss) after tax from continuing operations	38	24		51		89	51	
Profit / (Loss) after tax from discontinued operations	-	-		-		-	-	
Profit / (Loss) for the period	38	24	61.2%	51	(25.7%)	89	51	74.2%
PAT Margin for continued operations	4.8%	3.5%	135 bps	7.4%	(252 bps)	6.0%	3.4%	259 bps
EPS for continued operations	12.3	7.6	61.0%	16.5	(25.7%)	28.8	16.5	74.2%

Financial Summary - Standalone




								INDIA GLYCOLS LII
Particulars (In INR Cr)	Q2FY24	Q2FY23	Y-o-Y (%)	Q1FY24	Q-o-Q (%)	H1FY24	H1FY23	Y-o-Y (%)
evenue from operations (net of excise)	775	670	15.8%	688	12.7%	1,463	1,477	(1.0%)
ther Income	11	8		6		17	15	
otal Income	786	677	16.1%	694	13.3%	1,480	1,492	(0.9%)
ost of Material Consumed	499	425		397		895	956	
of Sales	63.4%	62.8%		57.2%		60.5%	64.0%	
mployee Benefit Expenses	23	20		22		45	39	
of Sales	2.9%	2.9%		3.2%		3.0%	2.6%	
ther Expenses	160	159		173		333	354	
of Sales	20.4%	23.5%		25.0%		22.5%	23.7%	
BITDA	105	73	43.1%	101	3.5%	206	144	43.4%
BITDA Margin	13.3%	10.8%	252 bps	14.6%	(127 bps)	13.9%	9.6%	430 bps
epreciation	28	20		21		48	41	
віт	77	53	45.4%	81	(4.8%)	158	103	52.9%
nance Cost	29	23		28		57	43	
xceptional Items	-	-		-		-	-	
nare of net profit / (loss) of joint venture	-	-		-		-	-	
вт	48	30	57.5%	53	(10.1%)	101	60	67.5%
ax Expenses	12	8		13		25	15	
rofit / (Loss) after tax from continuing operations	36	22		41		76	45	
rofit / (Loss) after tax from discontinued operations	-	-		-		-	-	
rofit / (Loss) for the period	36	22	58.7%	41	(12.0%)	76	45	68.2%
AT Margin for continued operations	4.5%	3.3%	122 bps	5.8%	(131 bps)	5.1%	3.0%	212 bps
PS for continued operations	11.5	7.3	57.7%	13.1	(12.0%)	24.6	14.6	68.2%
			_					


Segment Performance - Consolidated



(In INR Cr)	Q2FY24	Q2FY23	% YoY	Q1FY24	% QoQ	H1FY24	H1FY23	Y-o-Y (%)
Bio-based Specialities and Performance Chemicals (BSPC)								
Net Revenue	508	442	14.8%	401	26.4%	909	991	(8.3%)
EBIT	42	28	46.4%	41	0.7%	83	52	58.6%
% margin	8.2%	6.4%	177 bps	10.3%	(210 bps)	9.1%	5.3%	385 bps
Portable Spirits (PS)								
Net Revenue	221	175	26.1%	235	(6.1%)	456	380	19.9%
EBIT	40	23	72.6%	43	(7.3%)	83	45	84.7%
% margin	18.0%	13.2%	487 bps	18.3%	(25 bps)	18.2%	11.8%	637 bps
Ennature Biopharma								
Net Revenue	46	52	(11.6%)	53	(11.9%)	99	107	(7.4%)
EBIT	7	13	(48.3%)	13	(46.1%)	20	27	(27.0%)
% margin	14.9%	25.5%	(1,057 bps)	24.3%	(943 bps)	19.9%	25.2%	(534 bps)









IGL at a Glance





Go Green

1st in the world to use Innovative Green Technologies to manufacture bio-based ethylene oxide & derivatives, glycols, glycol ethers and specialties.



Diversified product portfolio with inherent synergies

Bio-based Specialties, Bio-Polymers, Potable Spirits, Gases, Biofuels, Plant based APIs & Nutraceuticals, CarbonSmart range etc.



Global Standards

Compliance with stringent global standards of plant operations, quality and safety.



State-of-the-art manufacturing facilities

Integrated manufacturing facilities located at Kashipur, Gorakhpur and Dehradun, have been approved and certified by international agencies



Global customer & partnerships with reputed global companies

Work closely with global customers in the various industries; catering to high value-added green market constituting multinationals & large corporates




Strengthening Balance sheet

Gearing declined to 0.6x in FY23 from 0.8x in FY20

Amongst world's leading companies manufacturing green technology-based bulk, specialty and performance chemicals, potable spirits, industrial and nutraceuticals

Key Milestones








Segments	Bio-based Specialities And Performance Chemicals (BSPC)	Potable Spirits (PS)	Ennature Biopharma
Revenue Mix (Consol. FY23)	Net revenue share 64%	Net revenue share 28%	Net revenue share 7%
Products	 Bio-based Glycols (MEG, DEG, TEG and Heavy Glycols), Glycol Ethers & Acetates Ethylene Oxide Derivatives (EODs) (transferred to a JV company) Bio Fuel, Bio Polymers, Industrial Gases, Bio-Polymers Amines & Plasticizers New Areas – Bio-fuels, Bio-FMCG, CarbonSmart and Bio-Fertilizers 	 Indian-manufactured foreign liquor (IMFL) across Wiskey, Vodka and Rum segments Branded Country Liquor Extra Neutral Alcohol (ENA) 	 Plant based natural APIs Thiocolchicoside Lutin Curcuin Astaxanthin Nutraceuticals Liquid Nicotine & various salts Carotenoids
Applications	□ Food and Beverage, FMCG □ Health Care & Personal Care □ Paint, Coatings, Home Care □ Automotive sector □ Oil & gas, Metal and mining □ Textiles	 Beverages, Perfumery, Pharma, Personal Hygiene Lifestyle Retail 	 Pharmaceutical Personal Care Food colours, herbal and spice extracts Beverage, dietary supplement, functional food

JV with Clariant: Leaders in in bio-based ethoxylates and derivatives





• Subject to adjustment in accordance with the Business Transfer Agreement



Combining production and distribution capacity,

the joint venture is establishing to become a leading supplier of renewable materials to the rapidly growing consumer care market in India and neighbouring countries



Production facilities in India are supplying to local and global markets, thus one of the largest Green focused speciality chemicals (EO Derivative) company



Promote new age value added products such as EO-PO co-polymers and other speciality alkoxylates through sustainable green chemistry in the domestic market while expanding footprint in global markets



Exclusive rights to distribute Clariant's entire range of industrial and consumer Specialities business in India, Sri Lanka, Bangladesh and Nepal



Focusing on exports due to better margins

Focus on formulations, localization of products, exports of sustainable products

Leveraging synergies to create value–integrated manufacturing for bio-based products


FINISHED

GOODS

PROCESS

RAW MATERIAL









Kashipur

300-acre state of art integrated manufacturing complex

Fermentation - Molasses and Grain Based

Ethanol Distillation, Extra Purification

Biofuels

Grain based Ethanol

Ethylene Oxide, High purity EO

Glycols (MEG, DEG, TEG and derivatives)

Green solvents based on Glycol Ethers and Glycol

Ether Acetates

Specialities and Performance Chemicals

Branded CL Bottling

IMFL

Industrial Gases – Oxygen, Nitrogen, Argon, CO2



Gorakhpur

56-acre state of art distillation & bottling complex

Grain based Ethanol

Fermentation

Ethanol Distillation

Ethanol Extra Purification

Ethanol Bio Fuel Grade

Branded CL Bottling

IMFL bottling Tetra

IMFL Glass bottling



Dehradun

160,000 sqft state of art facility

High Purity Extraction

SCFE (Super Critical CO2)


Solvent Extraction

Aqueous Extraction

Bio Fermentation

R&D: Creating value through New Product Development; focus on Green Chemistry







Bio-based Specialities and Performance Chemicals (BSPC)



□ First in the world to manufacture ethylene oxide and glycols from bio-based feedstocks e.g. Molasses, Grain
 □ Largest manufacturer of Bio-based glycols and Bio-based Ethylene Oxide made from renewable feedstock i.e. Molasses
 □ Products for a number of end market areas – Automotive, Paints & Coatings, Oil & Gas, Personal Care, Home Care, Textiles, Food etc.
 □ Bio Fuels – Special Grade of Ethanol for petrol blending
 □ Glycol ethers and acetates: Only manufacturer in India to use a continuous process with world-renowned 'Sulzer Chemtech' technology. Reliable supply; integration of its captive feedstock of ethylene oxide and ethyl alcohol
 □ Industrial Gases: Cryogenic gases using pioneering air separation technology - Liquid Oxygen and Liquid Nitrogen for captive and external requirements. In addition, Argon, Beverage and Industrial Grade Liquid Carbon Di-oxide (LCO2), ETO (Ethylene Oxide & Carbon Dioxide Gas Mixtures) are produced
 □ Manufacturing of Biopolymers other hydrocolloids products with specialty PO derivatized guar

Potable Spirits (PS)



License for operations and sale of Country Liquor in the States of Uttar Pradesh and Uttarakhand. Also operates and sells Indian Made Foreign Liquor ("IMFL") from its own unit and few tie-up units
Company brands are available in the states of Uttarakhand, Uttar Pradesh, Delhi and Himachal Pradesh
Several IMLF brands and products launched – Amazing [™] Vodka, Single [™] Reserva Whiskey, Amazing Green Apple [™] , Amazing Orange and Amazing Plain , Soulmate Gin, V2O Orange Vodka and Zumba Lemoni
Registered supplier to Indian Defense forces through CSD, continuing brand premiumisation plan, will endeavor to introduce premium brands
Extra Neutral Alcohol (ENA), confirming to international standards; exported to Middle East, Africa and Sri Lanka, apart from being supplied to many of India's premium liquor brands.
ENA is also used as a reaction aid in the pharmaceutical industry and as a volatile carrier of flavours and fragrances
Tie-up with Bacardi for bottling of their products at the Kashipur bottling unit
Continuing brand premiumisation plan to introduce premium brands in Whisky and Vodka categories will further strengthening the Company's brand portfolio
Grain based ethanol has helped in pushing up PS segment margins and drive sales through improved competitiveness

Ennature Biopharma (EB)



Operates in the space of Nutraceuticals, Phytochemicals & health supplement ingredients. One of the leaders in Complex phytochemicals chemistry in India
Global leader in Thiocolchicoside, a highly potent muscle relaxant API
Advanced production capabilities, including organic certified Fluid extraction & ethanol (solvent) extraction, for production of Standardized Botanical Extract, Phytochemicals, Food Supplements, Spice Extracts and Active Pharmaceuticals Ingredients (API) of natural plant origin
Ennature maintains germ plasm for herbs like artemisia, stevia, rosemary, marigold and sage among others, in ~100 acres; maintained under experienced agronomists. These are transferred to farmers who have contract cultivation agreements with IGL for buy-back
Successful products in the recent past include Liquid Nicotine & various salts, for cigarette replacement therapy. Additionally, the Company has developed molecule Asiaticoside/ Madecassosides apart from existing Centella Asiatica for skin repair
Also launched Maxicuma (a curcumin formulation) in nanotized form which is more bioavailable than curcumin itself

IGL - Catering to diverse end markets



- Glycols are used for the manufacture of polyester yarn, fibre, film and resin and as an automobile coolant
- Bio-glycols cater to the beverage and food industry's packaging requirement of PET bottles and polyester film
- Ethyl / Butyl glycol ethers and its acetates, find application in the Textile, Oil & Gas, Paint and Coating, Automotive brake fluid, Pharma and Electronic Chemical industries
- **Performance chemicals** in automotive sector include brake fluid and anti-freeze coolant. Other areas are Textile, Agrochemicals, Paint, Oil & Gas, Personal Care, Detergents, Paper, Mining etc.
- **Power Alcohol** is used by Oil Manufacturing Companies ('OMC's) for blending in Petrol as per Govt. Policy
- ENA Extra Neutral Alcohol is high purity ethanol which is used in Beverages, Perfumery, Pharma, Personal Hygiene
- Industrial Gases have a wide range of use across chemical processing, Glass manufacturing, Healthcare, Metal fabrication/ production, Steel, Petroleum recovery and refining, Pulp & paper, Wastewater treatment, Electronics, Lighting, Construction, Food industry
- **Liquid CO2** is used in Food Industry (Carbonation of beer and soft drinks, Food Preservation & Transportation, Dry Ice), Manufacturing industry (CO2 welding, Foundries, Fire Extinguishers), Agriculture (Green houses, Grain silos)
- **ETO** is used in Sterilization of disposable medical devices, and other sterilization uses
- Food Quality Natural Gum has application in Frozen Foods, Ice-Cream, Bakeries, Beverages & Sauces
- Industrial Quality Natural Gum is used in Personal Care, Mining, Paper, Construction, Paint, Textile industries and Oil & Gas applications



Growth Drivers




	pects of growth of industry sectors being serviced by IGL – Personal Care, Automotive, Packaging, Beverages, Oil & E Care, Pharma, Nutraceuticals etc, Textiles – most expected to grow at near double digit or more
☐ Increasing	consumer awareness and demand for sustainable products
☐ Companies	s taking steps to significantly decrease carbon footprint in line with USDG targets
☐ Growing d	emand for natural and safer products in pharma, nutraceuticals, cosmeceuticals, food ingredients
	ally placed to seize the opportunity arising out the increasing demand for ingredients derived from renewable and CarbonSmart feed stocks; alternatives to ingredients derived from fossil fuels
☐ State-of-th	e-art of technology adopted to produce specialty chemicals of global quality standards
☐ Regular R	&D and innovation support for products as well as their applications
☐ IGL has es	stablished itself as a reliable partner for its customers, with high degree of sustainability
☐ Collaborat	ive R&D tie-ups with leading global players for forward and backward integration of products
☐ Success st	cories of IGL from the experiences so far will serve as the key driver of growth








In INR


Cr

















The difference between excluding and excluding discontinued business is Ethylene Oxide Derivatives business (EOD/Speciality Chemicals & Ethoxylate) transferred to JV


4-year Financial Trajectory - Consolidated

















RoE showing is inclusive and excluding discontinued business i.e. Ethylene Oxide Derivatives business (EOD/Speciality Chemicals & Ethoxylate) transferred to JV



Sustainability, ESG




Environment Stewardship

- World's first and largest producer of Bio-Based EO and its derivatives
- Next Generation CarbonSmart products from emissions (fossil carbon) collaboration with LanzaTech & consumer majors like Unilever and Lululemon
- Environment conservation by adopting best practices & Zero Liquid Discharge plants
- Ennature Bio-Pharma High purity plant-based APIs and Nutraceuticals and Cosmeceuticals
- GHG emissions monitoring as per GHG Protocol along with Life Cycle Impact Assessment of products in respect to various environment aspects

Social Accountability

- · Social criteria in consideration of company's relation with stakeholders and their issues
- Commitment towards Diversity, Human Rights & Grievances
- · Zero tolerance towards Child Labour, Bonded Labour and Discrimination in any form
- High Standards and occupational health and safety and maintaining conducive environment
- Commitment to community and employee welfare



Management & Ethical System Certifications - sustaining for over a decade




























India Glycols Limited

CIN: L24111UR1983PLC009097

Ankur Jain

Company Secretary & Compliance Officer

Head office

2B, Sector-126, Noida

Gautam Budh Nagar

Uttar Pradesh 201304

Tel: +91-120-6860000, 3090100, 3090200

Fax: +91-120-3090111

Email: investor.relations@indiaglycols.com

Ernst & Young LLP

Runjhun Jain

runjhun.jain1@in.ey.com

Rohit Anand

rohit.anand4@in.ey.com

Riddhant Kapur

Riddhant.kapur@in.ey.com

